Loading quotes...

Forecast

The analysts' average price target is €21.37 (-7.65%). The median is €21.97 (-5.06%).

Buy	15
Hold	20
Sell	1

News Go to news feed

Baxter raises growth outlook and shows turnaround progress

At the Wells Fargo conference Baxter reported turnaround progress with 5% operational growth in Q2 and raised its 2026 full-year forecast to 2–3%. The company completed a $860m buyback program, used $600m to pay down debt and aims for net debt/EBITDA below 3x by the end of 2026. Management plans a reorganization into independent P&L units and the GPS program to drive performance, but sees ongoing weaknesses in infusion systems, injectables and IV solutions and expects 2027 headwinds from expiring TSAs and the loss of one-off effects. » More on de.investing.com
John Rogers to become Baxter CFO on October 1, 2026

Baxter appoints John Rogers as executive vice president and chief financial officer, effective October 1, 2026. Rogers joins from Smith+Nephew, was previously CFO at WPP and held leadership roles at J Sainsbury; he will report to Andrew Hider and is expected to help strengthen the balance sheet and support transformation initiatives. Baxter simultaneously confirmed its full-year 2026 financial guidance. » More on de.investing.com
Baxter increases buyback offer for bonds to 600 million US dollars

Baxter has raised the maximum repurchase amount for its cash tender offers from $500 million to $600 million. The company is accepting in full the bonds maturing in 2051, 2046 and 2043 that were validly tendered by the early tender deadline, while only about 31.37% pro rata of the 2032 notes will be accepted. Early tenderers will receive a premium of $30 per $1,000 principal; the submitted offers are expected to be settled on August 20, 2026 and the offers run as scheduled until September 1, 2026. Total consideration ranges by maturity from approximately $587.34 to $867.59 per $1,000 principal; accepted principal amounts are about $422.0 million (2051), $132.2 million (2046), $72.7 million (2043) and $236.9 million (2032). » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Baxter International has already paid €0.0348 in dividends. The last payout was in October.

Financials

In the last quarter, Baxter International had revenue of €2.63bn and net profit of €259.56m

(EUR)	September 2026	YoY
Revenue	2.63bn	8.76%
Gross profit	877.55m	8.40%
Net profit	259.56m	762.17%
EBITDA	422m	16.25%

Fundamentals

Metric	Value
Market capitalization	€11.9bn
Number of shares	517.35m
52-week high/low	€26.90 - €14.11
Dividend yield	0.15%
Dividends TTM	€0.0348
Beta	0.67
P/E ratio	-18.59
PEG ratio	0.10
P/B ratio	2.04
P/S ratio	1.14

Company profile

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Name	Baxter International
CEO	Andrew Hider
Headquarters	Deerfield, il USA
Website	baxter.com
Sector	Health Care
Industry	Health Care Technology
IPO	25/06/2008
Employees	37,500